IDEAS home Printed from https://ideas.repec.org/h/ito/pchaps/231763.html
   My bibliography  Save this book chapter

Convalescent Plasma: An Evidence-Based Old Therapy to Treat Novel Coronavirus Patients

In: Biotechnology to Combat COVID-19

Author

Listed:
  • Saurabh Kumar
  • Chandra Devi
  • Subhabrata Sarkar
  • Vivek Kumar Garg
  • Priyanka Choudhary
  • Madhu Chopra
  • Vinit Sharma
  • Ravi Prakash

Abstract

Novel Coronavirus (nCoV-2019) is a highly infectious viral outbreak that has so far infected more than 110 million people worldwide. Fast viral transmission and high infection rates have severely affected the entire population, especially the old aged and comorbid individuals leaving significantly less time to find some effective treatment strategy. In these challenging times, convalescent plasma (CP) therapy came as a ray of hope to save humankind. It is a form of passive immunization that has been used to treat various infectious diseases since 1890, including the 1918 Spanish flu, 2002/03 SARS-CoV, 2009 H1N1, 2012 MERS-CoV, and 2014 Ebola outbreak. The transfusion includes administration of CP containing a high value of neutralizing antibodies against the virus in hospitalized patients. This chapter summarizes the potential outcome of CP therapy in the treatment of nCoV-2019 patients.

Suggested Citation

  • Saurabh Kumar & Chandra Devi & Subhabrata Sarkar & Vivek Kumar Garg & Priyanka Choudhary & Madhu Chopra & Vinit Sharma & Ravi Prakash, 2022. "Convalescent Plasma: An Evidence-Based Old Therapy to Treat Novel Coronavirus Patients," Chapters, in: Megha Agrawal & Shyamasri Biswas (ed.), Biotechnology to Combat COVID-19, IntechOpen.
    • Handle: RePEc:ito:pchaps:231763
    DOI: 10.5772/intechopen.97073
    as

    Download full text from publisher

    File URL: https://www.intechopen.com/chapters/76142
    Download Restriction: no
    File URL: https://libkey.io/10.5772/intechopen.97073?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    nCoV-2019; CP therapy; viral infection; neutralizing antibody;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ito:pchaps:231763. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Slobodan Momcilovic (email available below). General contact details of provider: http://www.intechopen.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.